CN102245610B - 吡咯并三嗪激酶抑制剂 - Google Patents

吡咯并三嗪激酶抑制剂 Download PDF

Info

Publication number
CN102245610B
CN102245610B CN200980149134.7A CN200980149134A CN102245610B CN 102245610 B CN102245610 B CN 102245610B CN 200980149134 A CN200980149134 A CN 200980149134A CN 102245610 B CN102245610 B CN 102245610B
Authority
CN
China
Prior art keywords
methyl
pyrazol
pyrrolo
piperazin
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980149134.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102245610A (zh
Inventor
阿肖克.V.普兰达尔
戴维.B.弗伦尼森
穆索尼.G.卡莫
拉尔古迪.S.哈里克里什南
马克.G.索尔尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102245610A publication Critical patent/CN102245610A/zh
Application granted granted Critical
Publication of CN102245610B publication Critical patent/CN102245610B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200980149134.7A 2008-10-08 2009-10-08 吡咯并三嗪激酶抑制剂 Expired - Fee Related CN102245610B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10362008P 2008-10-08 2008-10-08
US61/103,620 2008-10-08
PCT/US2009/059945 WO2010042684A1 (en) 2008-10-08 2009-10-08 Pyrrolotriazine kinase inhibitors

Publications (2)

Publication Number Publication Date
CN102245610A CN102245610A (zh) 2011-11-16
CN102245610B true CN102245610B (zh) 2014-04-30

Family

ID=41664941

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980149134.7A Expired - Fee Related CN102245610B (zh) 2008-10-08 2009-10-08 吡咯并三嗪激酶抑制剂

Country Status (5)

Country Link
US (1) US8445676B2 (enExample)
EP (1) EP2344504B1 (enExample)
JP (1) JP5592890B2 (enExample)
CN (1) CN102245610B (enExample)
WO (1) WO2010042684A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111531A1 (en) * 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN104016983B (zh) * 2013-10-08 2018-11-02 上海创诺制药有限公司 吡咯并三嗪类衍生物及其制法和用途
WO2015051500A1 (zh) * 2013-10-08 2015-04-16 上海创诺制药有限公司 吡咯并三嗪类衍生物及其制法和用途
NZ721726A (en) * 2013-12-17 2021-07-30 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN104974163B (zh) * 2014-04-14 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US10550125B2 (en) * 2015-10-20 2020-02-04 Bristol-Myers Squibb Company Prodrugs of imidazotriazine compounds as CK2 inhibitors
ES2877198T3 (es) * 2016-07-14 2021-11-16 Lilly Co Eli Inhibidores de JAK1
WO2021257863A1 (en) * 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
EP4493558A1 (en) 2022-03-17 2025-01-22 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CA3246424A1 (en) 2022-04-08 2023-10-12 SHY Therapeutics LLC Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1351498A (zh) * 1999-05-21 2002-05-29 布里斯托尔-迈尔斯斯奎布公司 激酶的吡咯并三嗪抑制剂
WO2005066176A1 (en) * 2003-12-29 2005-07-21 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
CN1771234A (zh) * 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂的制备方法
WO2007005708A1 (en) * 2005-07-01 2007-01-11 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
WO2007061882A3 (en) * 2005-11-18 2007-08-16 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
WO2008021924A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008005956A3 (en) * 2006-07-07 2008-03-06 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
WO2008057994A2 (en) * 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009042543A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2009111531A1 (en) * 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1351498A (zh) * 1999-05-21 2002-05-29 布里斯托尔-迈尔斯斯奎布公司 激酶的吡咯并三嗪抑制剂
CN1771234A (zh) * 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂的制备方法
WO2005066176A1 (en) * 2003-12-29 2005-07-21 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
WO2007005708A1 (en) * 2005-07-01 2007-01-11 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007061882A3 (en) * 2005-11-18 2007-08-16 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008005956A3 (en) * 2006-07-07 2008-03-06 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
WO2008021924A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057994A2 (en) * 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009042543A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2009111531A1 (en) * 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors;Kyoung Soon Kim et al;《Bioorganic & Medicinal Chemistry Letters》;20060530;第16卷;3937-3942 *
新型吡咯并[2, 1-f][1, 2, 4] 三嗪酪氨酸激酶抑制剂的设计与合成;徐中轩 等;《合成化学》;20090620;第17卷(第3期);304-308 *

Also Published As

Publication number Publication date
JP5592890B2 (ja) 2014-09-17
US20110294816A1 (en) 2011-12-01
WO2010042684A1 (en) 2010-04-15
JP2012505234A (ja) 2012-03-01
US8445676B2 (en) 2013-05-21
CN102245610A (zh) 2011-11-16
EP2344504A1 (en) 2011-07-20
WO2010042684A4 (en) 2010-07-08
EP2344504B1 (en) 2014-06-04

Similar Documents

Publication Publication Date Title
CN102245610B (zh) 吡咯并三嗪激酶抑制剂
JP5095626B2 (ja) ピロロトリアジンキナーゼ阻害剤
EP2049542B1 (en) Pyrrolotriazine kinase inhibitors
CN101687874B (zh) 吡咯并三嗪激酶抑制剂
KR102037619B1 (ko) ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
EP2051980B1 (en) Pyrrolotriazine kinase inhibitors
CN102933572B (zh) 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法
CN101679406B (zh) 用作激酶抑制剂的噻唑基化合物
JP5180967B2 (ja) ピロロトリアジンキナーゼ阻害剤
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
JP5286281B2 (ja) アミノピラゾールキナーゼ阻害剤
ES2365814T3 (es) Inhibidores de cinasa de pirrolotriazina.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140430

Termination date: 20151008

EXPY Termination of patent right or utility model